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In the 1960s, the thymus was an organ of
mystery. Although it was full of lympho-
cytes, they made no antibodies. Further-
more, thymectomy (in mature animals)
failed to produce immunological inade-
quacy. This situation changed when J.F.A.P.
Miller did neonatal thymectomy, which was
indeed followed by a syndrome including
crippling of the immune response (1–3).
The possible role of the thymus was the
focus of a several-day symposium orga-
nized by Robert A. Good in November,
1962 in Minneapolis. Its proceedings, The
Thymus in Immunobiology, summarized
the clinical and experimental data (4).
This mystery organ intrigued me. Sys-
temically, immunized animals did not
make antibody in the thymus as they did
in lymph nodes or spleen. Maybe, we
thought, there was some kind of blood–
thymus barrier, which prevented systemic
antigen from interacting with thymocytes
in the thymic parenchyma. We used adop-
tive transfer of syngeneic cells into irradi-
ated recipients. In this model, spleen cell
suspensions responded to sheep erythro-
cyte (sheep red blood cells, SRBC) antigens
by making hemolytic antibody in the recip-
ient spleens and serum. Would thymus cell
suspensions similarly prepared (so as to
break any blood–thymus barrier) do the
same?
I was a young investigator working in
the late David W. Talmage’s lab at the
University of Colorado Medical School in
Denver. It was a stimulating environment.
Edward A. Chaperon and R. Faser Triplett
were post-doctoral fellows. On day 0, the
mice were irradiated and then injected i.v.
with spleen cells or thymus cells. On day 1,
we injected the SRBC antigen IV. On day
5, we sacrificed the mice and looked for
anti-SRBC-producing cells in the recipient
spleens. The results were clear-cut. Recip-
ients of donor spleen cells made many
antibody-producing cells while recipients
of donor thymus cells did not. Perhaps, we
thought, 4-days of exposure to antigen after
transfer might have been sufficient to get
the mature spleen cells to make antibody
but insufficient for the (putatively) imma-
ture thymocytes to do the same. We needed
to lengthen the protocol.
The next experiments were identical on
days 0 and 1, but on day-4 recipients got
a booster injection of SRBC antigen, and
we planned to sacrifice on day 8. This
worked well in the group that received
spleen cells but the recipients of thymus
cells (the test group) were all dead by day 8.
We figured that this represented radiation
death in the thymus recipients, whereas the
spleen recipients survived because of the
hematopoietic stem cells in the inoculum.
We knew of the radio-protective effects
of bone marrow cells, so it made sense to
add an aliquot of such cells to the thy-
mus inoculum. Indeed, the recipients of
thymus-plus-bone marrow survived until
day 8, but to our surprise, these recipients
produced almost as much antibody as did
spleen recipients. (Later we added a new
group as another control, i.e., bone mar-
row cells only. They caused no significant
antibody production.)
We called this phenomenon “thymus–
marrow synergism,” and it was the first
demonstration that two (presumably lym-
phoid) cell populations were needed for
significant antibody production. We spec-
ulated that one sort of cell (the “effector”)
made the antibody while another variety
of cell from the other inoculum performed
in an “auxiliary” mode. On the basis of
indirect evidence, we postulated that the
bone marrow provided the effector cells
and the thymus cells were “auxiliary.” Sup-
port for this view had to await the definitive
experiments by others.
Our experiments were published in
1966 in Proc. Soc. Exptl. Biol. Med. (5). The
paper was widely acknowledged to have
demonstrated cell–cell interaction in the
antibody response. Additional findings by
the three of us were considered important
enough many years later when they were
chosen as the first article to be mentioned in
the Journal of Immunology’s new historical
series, Pillars of Immunology.
This discovery was unexpected – almost
representing serendipity. Not everyone was
convinced. However, others used the para-
digm to provide further elucidation of the
mechanism of thymus–marrow synergism.
Mitchell and Miller made great progress
by identifying the antibody-forming cell as
originating in the bone marrow (6). Addi-
tionally, Avrion Mitchison added the bril-
liant insight that the carrier effect was an
example of T–B collaboration where the
anti-hapten antibody was made by bone
marrow-derived cells while the thymus-
derived cells provided “help” (7–9).
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